港股異動 | 凱萊英大漲超11% 4日連漲20% 機構唱好+北水加倉
格隆匯12月28日丨凱萊英(6821.HK)大幅拉昇漲超11%,4日連漲超20%,現報107.5港元創一個半月新高,總市值重回400億港元上方。浙商證券最新報吿稱,從產能變化看凱萊英成長空間,2021-2025年公司收入複合增速望進一步加速至30%-34%。該行看好公司小分子CDMO全球TOP2和新興業務加速下市值天花板突破。上週五,南向資金再度增持凱萊英1.34萬股,連續7日增持。目前港股通共持有公司602.11萬股。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.